Hypertrophic Cardiomyopathy Therapeutics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 1.80 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Hypertrophic Cardiomyopathy Therapeutics Market Analysis
The Hypertrophic Cardiomyopathy Therapeutics Market is expected to grow at a CAGR of 1.8% over the forecast period (2022-2027).
Covid-19 has a considerable effect on all major organ systems. Due to the rising number of cases of Covid-19 in the initial stages of the pandemic, all hospitals around the world canceled medical visits and the target population remained indoors fearing the infection. However, the underlying cardiac disease, including heart failure (HF), is associated with increased SARS-CoV-2-related mortality. Thus, the risk of hypertrophic cardiomyopathy (HCM) increased during the pandemic. The research and developments increased for the development of advanced therapeutics for the treatment of HCM patients infected with Covid-19. An international multicenter study was conducted, and the results were published in the article 'Impact of SARS-Cov-2 Infection in Patients with Hypertrophic Cardiomyopathy: Results of an International Multicentre Registry' in June 2022. As per the study results, 1/4th of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Additionally, age and cardiac features related to HCM showed an increased risk of mortality. Thus, this generated demand for the development of drugs of therapies for patient survival during the pandemic. Therefore, the pandemic is predicted to significantly impact the market studied.
Factors such as the rise in obesity and sedentary lifestyle population coupled with new product development for targeted cardiac disorders are expected to positively impact the market growth.
The market is driven primarily by the global burden of obesity and the sedentary lifestyle of the population. For instance, the data updated by World Health Organization (WHO) in June 2021 shows that obesity has increased globally, and it has tripled in the past two decades. In addition, the World Population Review's survey 'Obesity Rates by Country 2022' results show that about 13% of adults are obese and about 39% of adults are overweight globally. As per the article 'Clinical Significance of Overweight in Patients with Hypertrophic Cardiomyopathy' published in October 2021, overweight patients were associated with more heart failure (HF) rehospitalization in HCM patients and being overweight was an independent determinant of major adverse cardiovascular and cerebral events (MACCE) in HCM patients. Thus, the burden of obesity and overweight coupled with the risk of heart failure among hypertrophic cardiomyopathy (HCM) patients with obesity demands the availability of therapeutics for treatment. Thereby driving the market growth.
Additionally, the data updated for 'Hypertrophic Cardiomyopathy' by the 'National Library of Medicine' in June 2022, the prevalence of HCM in the general population around the world is 0.2%, as determined from echocardiographic studies. Additionally, as per the source mentioned above, morphologic evidence is found in approximately 25% of first-degree relatives of patients with HCM. Thus, the high burden of the disease is demanding therapeutics for the treatment and patient survival. Therefore, it is expected to propel the studied market growth over the forecast period.
Therefore, owing to the above-mentioned factors the market studied is expected to grow over the forecast period. However, the technological advancement in devices is one of the major factors that is anticipated to hinder the market growth.
Hypertrophic Cardiomyopathy Therapeutics Market Trends
This section covers the major market trends shaping the Hypertrophic Cardiomyopathy Therapeutics Market according to our research experts:
Beta-Adrenergic Blocking Agents Segment is Expected to Witness Growth Over the Forecast Period
Beta-blockers function by obstructing the actions of the hormone epinephrine and referred to as adrenaline. Beta-blockers reduce blood pressure by causing the heart to beat more gradually and gently. Beta-adrenergic blockers (β-blockers) are an important class of drugs that are primarily prescribed by cardiologists for the treatment of various heart diseases including thickened heart muscle (hypertrophic cardiomyopathy (HCM)), among others. Thus, owing to the efficacy of the beta-blockers for the treatment of HCM is predicted to fuel the segment growth over the analysis period.
Various research shows that beta-adrenergic blockers prevent catecholamines from binding to the receptor sites which results in a decrease in heart rate, heart contraction, and blood pressure. This shows the effects of beta-adrenergic blockers on the heart, lungs, and blood vessels. In addition, the article 'Beta-Blockers and Exercise Hemodynamics in Hypertrophic Cardiomyopathy' published in April 2022 stated that, despite a lack of trial evidence, beta-blockers have long been regarded as a first-line treatment for HCM. Therefore, the adoption of Beta-Adrenergic Blocking Agents or beta-blockers for the treatment of HCM is expected to boost segment growth.
Moreover, the recent developments and clinical trials in the segment are increasing recently. For instance, in August 2022, a clinical trial was registered titled 'A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM) (DISCOVER-HCM)' with the objective to evaluate the safety of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) treated in the real-world setting. The patients of the trial will be given beta-blocker (BB)/non-dihydropyridine(non-DHP) calcium channel blocker (CCB)/disopyramide as prescribed by a physician. Such advancements in the segment are expected to fuel segment growth.
Therefore, owing to the factors mentioned above, the segment is anticipated to witness growth over the forecast period.
North America is Expected to Dominate the Market and Expected to do Same in the Forecast Period
North America is anticipated to witness growth over the forecast period and dominate the market. Among other countries in the region, the United States is leading the market, due to factors such as an increase in healthcare expenditure, increasing research and developments, and a rising prevalence of various communicable or non-communicable diseases. Additionally, the rising geriatric population across the United States is the primary driver for the United States syndromic multiplex diagnostic market.
For instance, as per the data submitted in the article 'Stable Rates of Obstructive Hypertrophic Cardiomyopathy in a Contemporary Era' published in January 2022, hypertrophic cardiomyopathy is the most prevalent type of inherited hereditary heart disease and, the prevalence of HCM in the United States is estimated to be 1 in 500 persons, yet a sizable portion of patients go undiagnosed. Thus, such a high burden of the disease is demanding therapeutics for the treatment and patient survival. Therefore, it is expected to propel the studied market growth in the region over the forecast period.
Moreover, the development activities by the market players in the form of product launches, acquisitions, mergers, and investments are also expected to enhance the market growth. For example, in October 2021, MyoKardia, Inc. registered a Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM).
In addition, in February 2022, Cytokinetics, Incorporated opened enrollment for SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), a Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Aficamten is a next-generation cardiac myosin inhibitor in development for the potential treatment of HCM. SEQUOIA-HCM builds on the positive results from REDWOOD-HCM, a Phase 2 clinical trial of aficamten, that demonstrated that treatment with aficamten for 10 weeks resulted in reductions from baseline compared to placebo in the average resting left ventricular outflow tract pressure gradient (LVOT-G) and the average post-Valsalva LVOT-G, with no treatment interruptions or discontinuations, nor any treatment-related serious adverse events. Thus, these increasing developments in the market across all the countries in North America are anticipated to drive market growth over the forecast period in the country.
Therefore, owing to the factors mentioned above, North America is predicted to be the major market for syndromic multiplex diagnostics, which is expected to witness growth over the forecast period.
Hypertrophic Cardiomyopathy Therapeutics Industry Overview
The Hypertrophic Cardiomyopathy Therapeutics Market is moderately consolidated competitive and consists of of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently domianting the market are Sanofi S.A., Astra Zeneca Plc, Pfizer Inc, ADVANZ PHARMACorp (Concordia Healthcare Corp), Gilead Sciences Inc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Mylan N.V., Bayer AG.
Hypertrophic Cardiomyopathy Therapeutics Market Leaders
-
AstraZeneca Plc
-
Bayer AG
-
Sanofi S.A.
-
Merck & Co., Inc
-
Novartis AG
*Disclaimer: Major Players sorted in no particular order
Hypertrophic Cardiomyopathy Therapeutics Market News
- In August 2022, Bristol-Myers Squibb Company funded the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) symposium to be organized at the European Society of Cardiology (ESC) Congress through an unrestricted educational grant. The focus of the symposium is to discuss innovative therapeutic approaches in hypertrophic cardiomyopathy.
- In April 2022, Bristol Myers received approval from Food and Drug Administration (FDA) for its Camzyos (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms.
Hypertrophic Cardiomyopathy Therapeutics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rise in Obese and Sedentary Lifestyle Population
- 4.2.2 New Product Development for Targeted Cardiac Disorders
-
4.3 Market Restraints
- 4.3.1 Technological Advancement in Devices
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Drug Class
- 5.1.1 Antiarrhythmic Agents
- 5.1.2 Anticoagulants
- 5.1.3 Beta Adrenergic Blocking Agents
- 5.1.4 Calcium Channel Blockers
- 5.1.5 Others
-
5.2 Geography
- 5.2.1 North America
- 5.2.1.1 United States
- 5.2.1.2 Canada
- 5.2.1.3 Mexico
- 5.2.2 Europe
- 5.2.2.1 Germany
- 5.2.2.2 United Kingdom
- 5.2.2.3 France
- 5.2.2.4 Italy
- 5.2.2.5 Spain
- 5.2.2.6 Rest of Europe
- 5.2.3 Asia-Pacific
- 5.2.3.1 China
- 5.2.3.2 Japan
- 5.2.3.3 India
- 5.2.3.4 Australia
- 5.2.3.5 South Korea
- 5.2.3.6 Rest of Asia-Pacific
- 5.2.4 Middle-East and Africa
- 5.2.4.1 GCC
- 5.2.4.2 South Africa
- 5.2.4.3 Rest of Middle-East and Africa
- 5.2.5 South America
- 5.2.5.1 Brazil
- 5.2.5.2 Argentina
- 5.2.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Astra Zeneca Plc
- 6.1.2 ADVANZ PHARMA Corp (Concordia Healthcare Corp)
- 6.1.3 Bayer AG
- 6.1.4 Gilead Sciences, Inc
- 6.1.5 Merck & Co., Inc
- 6.1.6 Viatris
- 6.1.7 Novartis AG
- 6.1.8 Pfizer, Inc
- 6.1.9 Sanofi S.A.
- 6.1.10 Teva Pharmaceutical Industries Ltd
- 6.1.11 CYTOKINETICS
- 6.1.12 Bristol-Myers Squibb Company (MyoKardia)
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityHypertrophic Cardiomyopathy Therapeutics Industry Segmentation
As per the scope of this report, hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease caused by a mutation in sarcomere protein genes that encodes for the contractile machinery of the heart. The Hypertrophic Cardiomyopathy Therapeutics Market is segmented by Drug Class (Antiarrhythmic Agents, Anticoagulants, Beta Adrenergic Blocking Agents, Calcium Channel Blockers, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Drug Class | Antiarrhythmic Agents | |
| Anticoagulants | ||
| Beta Adrenergic Blocking Agents | ||
| Calcium Channel Blockers | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Hypertrophic Cardiomyopathy Therapeutics Market Research FAQs
What is the current Global Hypertrophic Cardiomyopathy Therapeutics Market size?
The Global Hypertrophic Cardiomyopathy Therapeutics Market is projected to register a CAGR of 1.8% during the forecast period (2024-2029)
Who are the key players in Global Hypertrophic Cardiomyopathy Therapeutics Market?
AstraZeneca Plc, Bayer AG, Sanofi S.A., Merck & Co., Inc and Novartis AG are the major companies operating in the Global Hypertrophic Cardiomyopathy Therapeutics Market.
Which is the fastest growing region in Global Hypertrophic Cardiomyopathy Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Hypertrophic Cardiomyopathy Therapeutics Market?
In 2024, the North America accounts for the largest market share in Global Hypertrophic Cardiomyopathy Therapeutics Market.
What years does this Global Hypertrophic Cardiomyopathy Therapeutics Market cover?
The report covers the Global Hypertrophic Cardiomyopathy Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Hypertrophic Cardiomyopathy Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Hypertrophic Cardiomyopathy Industry Report
Statistics for the 2024 Hypertrophic Cardiomyopathy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Hypertrophic Cardiomyopathy analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
